Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Innovation Council · Running

Aeson® The World’s Only Bioprosthetic Auto-regulated Artificial Heart: From Total Artificial Heart (TAH) to Physiologic Heart Replacement Therapy (PHRT)

Coordinator
Carmat, France
Runs
1 October 2022 to 30 June 2025
Status
Running
EU funding
€2.5m
Total cost
€11.6m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190185733

What the project is doing

In the project's own words, from its summary on CORDIS.

At Carmat we have designed and developed Aeson®, the world’s most advanced total artificial heart (TAH), aiming to fulfill an unmet medical need by providing a credible therapeutic alternative to heart transplants for people suffering from end-stage biventricular heart failure. Aeson® is an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure.

The device is electro-hydraulically driven with a shape close to that of a human heart. Once the Aeson® is powered, it mimics the action of a normal heart, providing mechanical circulatory support and restoring normal blood flow through the body. Aeson® differs from other existing artificial hearts (or TAH – total artificial hearts) in its unique combination of three features: pulsatility, autoregulation and hemocompatibility.

With Aeson®, Carmat is creating a new therapeutic class of “physiologic heart replacement therapy” (PHRT).

Who is involved

OrganisationCityCountryRole
CarmatVelizy-VillacoublayFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI